Subbiah Subbiah V V Hu Hu MI MI Wirth Wirth LJ LJ Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study Lancet Diabetes Endocrinol Lancet Diabetes Endocrinol 2021 2021 9 9 491 491 501 501 10.1016/S2213-8587(21)00120-0 10.1016/S2213-8587(21)00120-0 supplied-pmid 34118198? Here, RET is linked to thyroid cancer.